Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

TEMENTS OF OPERATIONS (unaudited) Quarter Ended Twelve Months Ended December 31, December 31, 2008 2007 2008 2007 Revenues: Related party revenue $- $5,252,000 $2,401,000 $14,246,000 Research grants and contract revenue (44,000) - 400,000 55,000 License fees, milestones and other revenues 334,000 299,000 346,000 329,000 Total revenues 290,000 5,551,000 3,147,000 14,630,000 Costs and expenses: Research and development 962,000 5,212,000 11,161,000 22,339,000 Selling and marketing 654,000 576,000 1,099,000 1,024,000 General and administrative 2,394,000 2,319,000 8,987,000 11,535,000 Restructuring (260,000) 1,092,000 3,472,000 1,092,000 Contract settlement income from related party - - (5,652,000) - Total costs and expenses 3,750,000 9,199,000 19,067,000 35,990,000 Loss from operations (3,460,000) (3,648,000) (15,920,000) (21,360,000) Interest income 98,000 360,000 722,000 1,118,000 Interest expense related to warrants 1,566,000 1,053,000 (3,072,000) 3,878,000 Other expenses, net 4,000 23,000 4,000 - Foreign exchange gain (loss) 86,000 (381,000) (95,000) (1,680,000) Loss before income tax (1,706,000) (2,593,000) (18,361,000) (18,044,000) Income tax expense (151,000) (89,000) (245,000) (306,
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Calif., March 3 WaferGen Biosystems,Inc. (OTC Bulletin ... genotyping, cell biology and stem cell research systems,today ... company,s management,team. Kumar Kastury, Ph.D., director of assay ... development and John McEntee, director,of engineering, has been ...
... 3 NicOx S.A.,(Euronext Paris: COX) today announced ... the United States, which will assess the blood,pressure ... naproxen,using the Ambulatory Blood Pressure Monitoring (ABPM) technique. ... will together recruit a,total of around 420 osteoarthritis ...
... 2007 Revenue Increases 45% Recurring Disposables, ... Update on Partnered Magnetic Irrigated Catheter Launch Provided, ... reported financial results for the fourth quarter and full ... 2007, revenue increased 45% to $39.3 million,compared with $27.2 ...
Cached Biology Technology:WaferGen Announces Management Team Promotions 2WaferGen Announces Management Team Promotions 3WaferGen Announces Management Team Promotions 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Ghanaian Obstetrics and Gynecology residents say in-country training programs ... country to practice medicine, new University of Michigan research ... in developing countries is a key component to improving ... which aim to decrease maternal and child mortality. But ...
... Harvard-Affiliated McLean Hospital have been awarded a $1.9 million ... their research into creating human induced pluripotent (iPS) stem ... of cancer and other problems associated with other options ... made possible through the American Recovery and Reinvestment Act ...
... Department of the Interior, the National Oceanic and Atmospheric ... the BP/Deepwater Horizon oil spill announced today they have ... the Natural Resource Damage Assessment, a legal process to ... compensate the public for harm to natural resources and ...
Cached Biology News:In-country OB/GYN training programs contributed to retention of doctors in Ghana, U-M study shows 2In-country OB/GYN training programs contributed to retention of doctors in Ghana, U-M study shows 3McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 3
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Biology Products: